In Brief: Novartis
Executive Summary
Novartis: Transderm Scop (scopolamine) gains FDA "approvable" status April 22 for the prevention of nausea and vomiting associated with anesthesia and/or opiate analgesia. The former OTC product is now listed with prescription status...